341 Participants Needed

Data-Driven Decision-Making for Addiction

(D2A Oregon Trial)

GC
EC
Overseen ByErika Crable, PhD, MPH
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Chestnut Health Systems
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to enhance how Oregon decision makers use data to address the opioid and methamphetamine crises. It tests a new strategy for creating user-friendly data products that assist leaders in making informed decisions on substance use services. Participants include decision makers or advisors involved in substance use policy or service delivery, such as executive directors or case managers. The trial divides participants into two groups: one group helps design customized data tools, while the other receives standard data products. As an unphased trial, this study allows participants to directly influence the development of innovative tools that could significantly improve decision-making in substance use services.

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What prior data suggests that this implementation strategy is safe for decision-making?

Research shows no specific safety data for the Data-Driven Decision-Making for Addiction treatment. This project uses data to enhance decision-making for substance use services in Oregon. Labeled as "Not Applicable" for phase, the trial does not test a new drug or medical procedure, indicating no direct health risks to participants.

The project aims to provide better data to help prevent overdoses and improve substance use treatment. Participants will work with data tools, so the usual safety concerns of drug trials do not apply. This suggests the treatment is well-tolerated, as it involves using data rather than physical interventions.12345

Why are researchers excited about this trial?

Researchers are excited about the Data2Action Oregon Project because it uses cutting-edge data-driven decision-making to tackle addiction. Unlike traditional treatments that often involve medication or counseling, this project focuses on tailoring data products to help healthcare providers make more informed decisions. One unique feature is the collaborative design sessions (CDS) where providers co-design data products, ensuring they are customized to their specific needs. This personalized approach aims to improve treatment outcomes by offering insights that are directly relevant to the provider's context, potentially revolutionizing how addiction is managed.

What evidence suggests that this trial's methods could be effective for improving substance use services?

Research shows that Oregon has the worst access to substance use services in the U.S. and the highest rates of opioid and methamphetamine use. The Data2Action Oregon Project aims to address these problems by using data science, such as predictive modeling, to improve decision-making in substance use services. This trial includes two groups: one group will participate in co-design sessions (CDS) to tailor data products, while the other group will not participate in CDS and will receive standardized data products. Studies have shown that using data can enhance services, help prevent overdoses, and address gaps in substance use services. By providing important data to decision-makers, this project seeks to create more effective policies and increase access to necessary treatments. The goal is to make informed decisions that lead to better outcomes for people struggling with addiction.12346

Are You a Good Fit for This Trial?

This trial is for decision-makers in Oregon involved with community services, public health, justice, advocacy groups, and payers. They need comprehensive data to tackle substance use issues and the opioid/methamphetamine epidemics. Participants should be those seeking to improve resource allocation for substance use services and overdose prevention.

Inclusion Criteria

I am over 18 and make decisions in substance use services or policy.
I am over 18 and make decisions in substance use services or policy.

Exclusion Criteria

Not applicable.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Co-Design Sessions (CDS)

Counties participate in Co-Design Sessions to co-design and tailor data products with the study team.

Varies by condition

Data Product Release

Counties receive tailored or standardized data products depending on their group assignment.

Annually for up to two years

Follow-up

Participants are monitored for the impact of data products on substance use service gaps and service-recipient outcomes.

Up to 3 years

What Are the Treatments Tested in This Trial?

Interventions

  • Data2Action Oregon Project
Trial Overview The study tests a new strategy that helps these decision-makers by providing relevant data in easy-to-use formats (Data products). It involves Co-Design Sessions (CDS) where participants work together to identify what data they need and how it can best support their decisions.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: No CDSExperimental Treatment1 Intervention
Group II: CDSExperimental Treatment2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Chestnut Health Systems

Lead Sponsor

Trials
27
Recruited
24,500+

National Institute on Drug Abuse (NIDA)

Collaborator

Trials
2,658
Recruited
3,409,000+

University of California, San Diego

Collaborator

Trials
1,215
Recruited
1,593,000+

Published Research Related to This Trial

Missing data in substance use disorder (SUD) research can significantly hinder the reliability of findings, especially for underserved populations who may have unique reasons for data gaps.
The paper emphasizes the need for better statistical tools to address various types of missing data, highlighting that these gaps represent not just statistical issues but also lost narratives that can influence important policy and system decisions.
Addressing Missing Data in Substance Use Research: A Review and Data Justice-based Approach.King, C., Englander, H., Priest, KC., et al.[2022]
Visualizing adverse events in clinical trials using methods like dot plots and volcano plots can enhance communication about the severity, timing, and recurrence of harms, rather than just counting occurrences.
The study analyzed individual participant data from a randomized trial of gabapentin for neuropathic pain, demonstrating that effective visualizations can help stakeholders better understand the multidimensional nature of harms in clinical research.
Comparing the Value of Data Visualization Methods for Communicating Harms in Clinical Trials.Qureshi, R., Chen, X., Goerg, C., et al.[2022]
A systematic review of 108 adverse drug event (ADE) reporting systems revealed 1782 unique data fields, highlighting significant variability in how ADEs are reported, which complicates data comparison and aggregation across different systems.
Despite consistent reporting concepts, the lack of standardized terminology and the use of multiple drug and disease dictionaries hinder effective drug safety monitoring, suggesting a need for a common standardized dataset to improve ADE reporting and surveillance.
Adverse drug event reporting systems: a systematic review.Bailey, C., Peddie, D., Wickham, ME., et al.[2021]

Citations

Data2Action Oregon Project: Supporting Data-driven ...In 2022 national survey data, Oregon ranked last in the U.S. for access to substance use services and first in opioid and methamphetamine use. A recent state- ...
Data2Action Project: Supporting Decision-Making Related ...– Substance use disorder prevention. – Substance use service expansion (filling gaps). – Overdose prevention. – Identifying policy impacts. 2 ...
Supporting Data-driven Decision-Making for Substance ...In 2022 national survey data, Oregon ranked last in the U.S. for access to substance use services and first in opioid and methamphetamine use. A ...
Data-Driven Decision-Making for AddictionWhat data supports the effectiveness of the Data2Action Oregon Project treatment for addiction? The use of data science, such as predictive modeling and big ...
HEAL Data2Action Modeling and Economic Resource CenterThe MERC will support the application of health economics and modeling research to real-world decision making about services to prevent or treat opioid use ...
HEAL Data2Action (HD2A)The HEAL Data2Action (HD2A) program utilizes data to drive actions, aiming to reduce overdoses and enhance opioid use disorder treatment and pain ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security